ERBB2 and breast carcinoma: HER2 has emerged as an important therapeutic target in the treatment of HER2-overexpressing (HER2+) breast cancer [14] that is considered one of the most aggressive subtypes since it is associated with an increased risk of recurrence, higher mortality in the early stage of the disease, and drug resistance [15].